Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Opportunities and challenges of the pulmonary route for vaccination

The respiratory tract is an attractive target for the delivery of vaccine antigens.

Research

Preterm infants have deficient monocyte and lymphocyte cytokine responses to group B streptococcus

Group B streptococcus (GBS) is an important cause of early- and late-onset sepsis in the newborn. Preterm infants have markedly increased susceptibility...

Research

The changing epidemiology of invasive pneumococcal disease

We investigated trends in invasive pneumococcal disease (IPD) in Western Australia (WA).

Research

Vaccinating young adults against HPV: the importance of understanding health decision-making and behaviour

Vaccination of young teenage females against human papillomavirus (HPV) with a newly licenced quadrivalent vaccine designed to prevent cervical cancer and...

News & Events

The Kids Research Institute Australia leads WA arm of Australia’s first needle-free COVID-19 vaccine study

Enrolments for Australia’s first needle-free, gene-based COVID-19 vaccine study – to be led in WA by The Kids Research Institute Australia – are open.

News & Events

Video: Flu vaccine Q&A

It's that time of year again... Flu vaccine time! Watch Dr Chris Blyth answer commonly asked questions in the video below.

News & Events

The Kids Research Institute Australia research ensures kids are protected against whooping cough

Research by The Kids Research Institute Australia will soon ensure young children are better protected against whooping cough.

Infectious Disease Implementation Research

The Infectious Disease Implementation Research Team is a multi-disciplinary group researching the best way to implement infectious disease prevention and treatment strategies to improve the wellbeing of children and teenagers.

Research

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. 

Research

Influenza

Influenza (commonly known as the flu) is caused by a highly contagious virus spread mainly through coughing and sneezing. An annual flu vaccination is the most effective way to prevent flu outbreaks.